{'fraction_non_alphanumeric': 0.02931937172774869, 'fraction_numerical': 0.010471204188481676, 'mean_word_length': 5.978102189781022, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Asymptomatic atopy is associated with increased indoleamine 2,3‐dioxygenase activity and interleukin‐10 production during seasonal allergen exposure

Background Indoleamine 2,3‐dioxygenase (IDO) is a tryptophan (TRP)‐catabolizing enzyme with regulatory effects on T cells. T cell inhibition is achieved through both TRP depletion and TRP metabolite accumulation in specific local tissue microenvironments. The expression of IDO activity by different types of antigen‐presenting cells (APCs) has been shown to play a role in many instances of immunoregulation and tolerance induction. Induction of IDO after the engagement of the high‐affinity receptor for IgE, FcɛRI, on atopic monocytes has been suggested to regulate T cell responses in atopic disorders. Interleukin‐10 (IL‐10), a cytokine known for its down‐regulatory functions in the immune system, has recently been associated with the stable expression of IDO in mature tolerogenic dendritic cells.